NEW YORK, July 17 – Compugen has licensed its Gencarta database of annotated genomic, transcription, and proteomic data to Japanese biopharmaceutical company Kyowa-Hakko Kogyo, Compugen said Tuesday.
Financial details of the arrangement were not disclosed.
Kyowa-Hakko Kogyo, based in Tokyo, is Compugen’s second customer for Gencarta, which the company released in March. Gencarta uses Compugen’s Leads algorithm to provide annotation of the transcription factors that bridge genes and proteins. Leads takes into account alternative splicing, in which exons, or coding regions, on one gene can combine in different ways to form different proteins, according to the company.
"We chose Compugen's Gencarta database and mining tools because of its exceptional transcriptome analysis," stated Dr. Seiga Itoh, Senior Executive Officer, Drug Discovery Division, Kyowa-Hakko. "We expect that the integration of Compugen's proprietary and comprehensive gene and protein database into our research will significantly advance our drug discovery and development processes."
In April, Avalon Pharmaceuticals, of Gaithersburg, Md., agreed to license Gencarta, and Compugen agreed to collaborate with Avalon on drug and diagnostic target identification research. Under that agreement, Avalon paid Compugen an undisclosed cash sum and granted Compugen a portion of its equity.